Development of Pre-Erythrocytic Malaria Vaccines

前红细胞疟疾疫苗的开发

• 批准号: 8745642
• 负责人: ROBERT A SEDER
• 金额: $ 21万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8745642
• 关键词: Adjuvant; Antibodies; Antigens; Area; Attenuated; Biological Assay; Bite; Blood; CD8B1 gene; Clinical Trials; Culicidae; Cytoprotection; Dendritic Cells; Development; Dose; Drug Formulations; Effector Cell; Erythrocytes; Frequencies; Goals; Human; Immune; Immunity; Immunization; Immunologic Adjuvants; Infection; Interferon Type II; Liver; Malaria; Malaria Vaccines; Mediating; Modeling; Mus; Natural Killer Cells; Phase; Phase I Clinical Trials; Proteins; Radiation; Route; Schedule; Spleen; Sporozoite vaccine; Sporozoites; T cell response; T-Lymphocyte; Vaccines; Viral Vector; circumsporozoite protein; immunogenicity; monocyte; response

The major discovery this year are as follows. 1. Showed that radiation attenuated sporozoites administered intravenously into NHP induced potent CD4 and CD8+ T cell responses in blood and liver. Established that a high frequency of NK cells in the liver secrete IFN-g in response to stimulation providing an additional effector cell for protection. Furthermore, showed that monocytes and dendritic cells present SPZ antigen to T cells. 2. Completed a phase I clinical trial assessing whether irradiated PfSPZ given by the IV route is safe and protective in a dose escalation study. 3. Showed that an attenuated malaria vaccine ( PfSPZ Vaccine) confers high level protection in humans following an experimental challenge with malaria infection. 4. Showed that the dose of the PfSPZ Vaccine is critical for mediating immunity and protection.

今年的主要发现如下。